USP <788>
Method for particle counting in parenteral solutions.
Equipment for these workflows
Instruments with features that support this standard's requirements. Compliance is achieved by the user organization, not by the equipment alone.
Related articles
3 3 articlesParenteral Solutions in Argentina: What Changes Under ANMAT Regulation 5146/2026?
ANMAT Regulation 5146/2026 clarifies the requirements for closed manufacturing systems used in large-volume parenteral solutions. Learn how these requirements relate to pharmaceutical quality control and subvisible particle testing.
Subvisible Particles in Injectables: Analytical Criteria and Compliance with the Argentine Pharmacopoeia
Technical review of Argentine Pharmacopoeia requirements for subvisible particles in injectables, covering sample preparation, acceptance criteria, analytical limitations and HIAC 9703+ applications.
Why do some surfactants better protect therapeutic proteins against agitation-induced aggregation?
Protein and surfactant compete for the same air/water interface, and whichever arrives first determines the fate of the batch. Adsorption kinetics, not CMC, correlates with agitation-induced aggregation.
Stay in the loop
Get updates, articles and news by email.